Interpretation of the medical insurance reimbursement policy for gosatolizumab/Todavi

Gosatuzumab/Trodelvy (Trodelvy) is a new ADC drug that has attracted widespread attention in recent years. Its targeting molecule is Trop-2 protein, which is highly expressed in a variety of solid tumors, especially triple-negative tumorsbreast cancer (TNBC), so gosatuzumab is mainly used to treat patients with advanced TNBC who have failed previous multiple lines of treatment. Overseas, gosatuzumab has been approved by the U.S. FDA for indications such as TNBC, HR+/HER2- breast cancer, and urothelial cancer. It has shown good efficacy signals in multiple clinical studies, bringing new hope to patients who have failed traditional treatments.

In China, gosatuzumab under the trade name "Tudavi" was introduced by Gilead and has been officially approved in 2023 for the treatment of patients with unresectable or metastatic TNBC who have received more than two systemic therapies in the past. This population often faces the dilemma of limited treatment options and poor prognosis, and the launch of gosatuzumab provides an important treatment option for this group of patients. However, the drug has not yet been included in the national medical insurance list, which means that the cost of treatment must be borne by the patient themselves. According to market information, the price of one dose of gosatuzumab may be as high as RMB 10,000. The cost of a complete treatment cycle is considerable, especially for patients who require long-term maintenance treatment. The financial burden is heavy.

in the country, whether gosatuzumab is included in medical insurance is a focus of concern for many patients. Although it has not yet been reimbursed, some hospitals may be able to obtain drug support through charity assistance projects or clinical research pathways. Patients can consult oncologists or hospital pharmaceutical departments. Currently, gosatuzumab is still in the medical insurance gap, and it is recommended that patients who meet the indications evaluate whether to participate in drug assistance or apply for investigational treatment under the guidance of a doctor.

Reference materials:https://www.trodelvy.com/